Demonstrates high-level adenine production in E. coli, suggesting a robust manufacturing platform.
, and adaptive laboratory evolution for product tolerance. The resulting plasmid-free and antibiotic-free strain demonstrated superior genetic stability and industrial robustness, achieving an adenine titer of 4.76 g/L (0.18 g/L/h) during a 26-h fed-batch fermentation without selection pressure. This system maintained high cell density and minimal byproduct formation, with a conversion efficiency of 0.025 g/g glucose. To our knowledge, this is the first report of a high-level, plasmid-free adenine production system, establishing a robust platform for the scalable biobased manufacturing of nucleobase-derived ingredients.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: